MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NuMedii, Inc. today announced a strategic alliance with Aptalis Pharma to discover and develop new methods of treatment for certain gastrointestinal disorders and cystic fibrosis. The companies will use NuMedii’s predictive Big Data technology, which enables discovery of new uses for medicines with a higher probability of successful clinical development.
Under the terms of the agreement, NuMedii will provide Aptalis with proprietary, de-risked therapeutic candidates using its predictive Big Data technology. Aptalis will be responsible for all development and commercialization activities related to the products that it chooses to advance under the collaboration. NuMedii will receive an initial upfront payment along with development and commercial milestone payments plus royalties on sales of each product developed under the collaboration.
“We are pleased to collaborate with Aptalis to discover and develop innovative, effective therapies for unmet medical needs in gastrointestinal disorders and cystic fibrosis to improve the health and quality of care for patients around the world,” stated Gini Deshpande, PhD, NuMedii’s CEO and Founder. “NuMedii’s predictive Big Data discovery technology and its preclinical de-risking expertise are a great fit with Aptalis’ proven capabilities in formulation, clinical development and commercialization of new therapeutics.”
About NuMedii, Inc.
NuMedii discovers and de-risks effective new drugs by translating its predictive Big Data technology into therapies with a higher probability of therapeutic success. The company’s Big Data technology, originally developed at Stanford and licensed exclusively to NuMedii, consists of billions of data points of ever-increasing amounts of comprehensive disease, pharmacological and clinical data. NuMedii integrates these data with network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The company has successfully validated its Big Data technology as six of six drug candidates have demonstrated preclinical activity for the predicted new indication. NuMedii will partner with pharmaceutical companies for the development and commercialization of its proprietary therapeutic candidates. For more information, visit www.numedii.com.
Gini Deshpande, PhD, 650-521-6363
Founder and CEO